ANTIPODES PARTNERS Ltd Grows Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

ANTIPODES PARTNERS Ltd lifted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 115.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,034 shares of the company’s stock after buying an additional 553 shares during the quarter. ANTIPODES PARTNERS Ltd’s holdings in Structure Therapeutics were worth $28,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after buying an additional 312 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Structure Therapeutics by 120.0% in the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares in the last quarter. Money Concepts Capital Corp lifted its holdings in shares of Structure Therapeutics by 4.2% in the fourth quarter. Money Concepts Capital Corp now owns 21,031 shares of the company’s stock worth $570,000 after buying an additional 848 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock worth $115,000 after buying an additional 971 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Up 4.3 %

GPCR stock opened at $21.42 on Thursday. Structure Therapeutics Inc. has a twelve month low of $19.39 and a twelve month high of $62.74. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -28.95 and a beta of -2.35. The firm’s fifty day simple moving average is $25.60 and its two-hundred day simple moving average is $32.66.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities research analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. William Blair assumed coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating on the stock. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $81.29.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.